Your browser doesn't support javascript.
loading
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas, Elisabet; Alay, Ania; Martínez-Iniesta, Maria; Hernández-Madrigal, Miguel; Cordero, David; Gausachs, Mireia; Pros, Eva; Saigí, Maria; Busacca, Sara; Sharkley, Annabel J; Dawson, Alan; Palmero, Ramón; Ruffinelli, José C; Padrones, Susana; Aso, Samantha; Escobar, Ignacio; Ramos, Ricard; Llatjós, Roger; Vidal, August; Dorca, Eduard; Varela, Mar; Sánchez-Céspedes, Montse; Fennell, Dean; Muñoz-Pinedo, Cristina; Villanueva, Alberto; Solé, Xavi; Nadal, Ernest.
Affiliation
  • Aliagas E; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Alay A; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Martínez-Iniesta M; Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Hernández-Madrigal M; Chemoresistance group. Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Cordero D; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Gausachs M; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Pros E; Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Saigí M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain.
  • Busacca S; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Sharkley AJ; Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Badalona, Barcelona, Spain.
  • Dawson A; Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Badalona, Barcelona, Spain.
  • Palmero R; Department of Genetics and Genome Biology, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Ruffinelli JC; University of Sheffield Teaching Hospitals, Sheffield, UK.
  • Padrones S; Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK.
  • Aso S; Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Escobar I; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Ramos R; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Llatjós R; Department of Respiratory Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Vidal A; Department of Respiratory Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Dorca E; Department of Thoracic Surgery, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Varela M; Department of Thoracic Surgery, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Sánchez-Céspedes M; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Fennell D; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Muñoz-Pinedo C; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Villanueva A; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Barcelona, Spain.
  • Solé X; Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Badalona, Barcelona, Spain.
  • Nadal E; Department of Genetics and Genome Biology, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Br J Cancer ; 125(10): 1365-1376, 2021 11.
Article in En | MEDLINE | ID: mdl-34588615
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Benzimidazoles / Protein Kinase Inhibitors / Cyclin-Dependent Kinase 4 / Cyclin-Dependent Kinase 6 / Mesothelioma, Malignant / Aminopyridines Limits: Aged / Animals / Female / Humans / Male Language: En Journal: Br J Cancer Year: 2021 Document type: Article Affiliation country: Spain Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Benzimidazoles / Protein Kinase Inhibitors / Cyclin-Dependent Kinase 4 / Cyclin-Dependent Kinase 6 / Mesothelioma, Malignant / Aminopyridines Limits: Aged / Animals / Female / Humans / Male Language: En Journal: Br J Cancer Year: 2021 Document type: Article Affiliation country: Spain Country of publication: United kingdom